Drug Trial Radar · NCT06510504
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
370
Actual
Start
Aug 6, 2024
Primary completion
Sep 11, 2025
Study completion Sep 19, 2025
Sponsor
- Lead sponsor
- Bionomics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Conditions
- Social Anxiety Disorder
Interventions
225 mg BNC210Drug
225 mg BNC210
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking ChallengeTime frame: Assessed over a single visit: On the treatment day at Baseline (approximately 5 minutes pre-dose) and during the Public Speaking Challenge Performance Phase conducted at 65 to 70 minutes post-dose (following the Anticipation Phase that started at 60 min).
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
AFFIRM-1 Study Site
Encino, California
AFFIRM-1 Study Site
La Jolla, California
AFFIRM-1 Study Site
Los Angeles, California
AFFIRM-1 Study Site
Oceanside, California
AFFIRM-1 Study Site
San Diego, California
AFFIRM-1 Study Site
San Jose, California
AFFIRM-1 Study Site
Sherman Oaks, California
AFFIRM-1 Study Site
Temecula, California
AFFIRM-1 Study Site
Jacksonville, Florida
AFFIRM-1 Study Site
Lauderhill, Florida
AFFIRM-1 Study Site
Miami Lakes, Florida
AFFIRM-1 Study Site
Orlando, Florida
AFFIRM-1 Study Site
Tampa, Florida
AFFIRM-1 Study Site
Decatur, Georgia
AFFIRM-1 Study Site
Boston, Massachusetts
AFFIRM-1 Study Site
Boston, Massachusetts
AFFIRM-1 Study Site
Princeton, New Jersey
AFFIRM-1 Study Site
Brooklyn, New York
AFFIRM-1 Study Site
Charlotte, North Carolina
AFFIRM-1 Study Site
Media, Pennsylvania
AFFIRM-1 Study Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.